Way back when Novartis invested in personalised CAR-T cancer treatments being developed at the University of Pennsylvania, analysts pondered the tricky question: How can pharma companies profit from curing patients?
Hidden layers of regulation that control the activity of genes can produce drug-resistant, surviving cells. New research helps explain how therapy-resistant cancers arise — findings with important implications for the future of cancer therapy.
William French Anderson, one of the earliest pioneers of gene therapy, is set to be released from prison in the next month after nearly 12 years behind bars. He intends to resume a career in science.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
Researchers have used CRISPR to develop a pig model of Huntington’s disease that better mimics how the disease progresses in humans.
Newly appointed CEO of Novartis, Vas Narasimhan has his sights set on the gene therapy area as the next big development in the pharmaceutical industry.
Material left out of common processes for sequencing genetic material in cancer tumours may actually carry important information about why only some people respond to immunotherapy.
Experts in medicine and law are urging the US to allow for the replacement of mutation-bearing mitochondria to prevent fatal illnesses in children.
Combining a cancer therapy with a second drug therapy that helps suppress tumour blood vessels found in cancer cells can help to significantly reduce the spread of breast cancer tumours while also causing cancer cell death.
Genentech researchers have successfully found a way to attack the shield of drug-resistant, gram-negative bacteria known as the BamA enzyme.
Last week, a 13-year-old boy found himself at the centre of medical history in the US as he became the first to receive an FDA-approved gene therapy for an inherited form of blindness.